2nd Department of Ophthalmology, Attikon University Hospital, University of Athens, Athens, Greece.
Am J Ophthalmol. 2012 Apr;153(4):620-6. doi: 10.1016/j.ajo.2011.09.030. Epub 2012 Jan 21.
To assess pupil dynamics quantitatively in relation to the use of α1-adrenoceptor antagonists, which contribute to the features of intraoperative floppy iris syndrome, using a new, hand-held, digital pupillometer.
Prospective case-control study.
We studied 15 and 25 patients administered tamsulosin and alfuzosin, respectively, as well as 25 control patients. Resting pupil diameter and subsequent contraction, latency, constriction velocity, and dilation velocity were recorded using an electronic pupillometer. All pupil measurements were performed before and after pharmacologic dilation.
In predilation pupillary measurements, we detected a significant decrease in maximum pupillary diameter by 0.50±0.19 mm (P=.011) and in the mean percentage of diameter reduction after stimulation (5.23±2.42%, P=.035) in the tamsulosin group. Alfuzosin also induced a significant decrease in maximum pupillary diameter (0.49±0.17 mm, P=.005). Constriction velocity was significantly reduced by 0.70±0.20 m/s (P=.001) in the tamsulosin group and by 0.54±0.18 m/s (P=.004) in the alfuzosin group. In terms of postdilation measurements, maximum and minimum pupil diameters were reduced significantly only in the tamsulosin group (by 1.09±0.31 mm [P=.001] and by 0.89±0.36 mm [P=.016], respectively).
We describe a reliable, accurate, and rapid method to acquire quantitative pupil measurements and identify the tendency for intraoperative floppy iris syndrome before cataract surgery after the use of alfuzosin and tamsulosin. This investigation also analyzed the similarities and differences induced by the 2 drugs in predilation and postdilation pupil dynamics, demonstrating that tamsulosin is more potent than alfuzosin in inducing intraoperative floppy iris syndrome.
使用新型手持式数字瞳孔计,定量评估与术中虹膜松软综合征特征相关的 α1-肾上腺素能受体拮抗剂的瞳孔动力学。
前瞻性病例对照研究。
我们分别研究了服用坦索罗辛和阿夫唑嗪的 15 例和 25 例患者,以及 25 例对照患者。使用电子瞳孔计记录静息瞳孔直径和随后的收缩、潜伏期、收缩速度和扩张速度。所有瞳孔测量均在药物扩张前后进行。
在预扩张瞳孔测量中,我们发现坦索罗辛组最大瞳孔直径显著减小 0.50±0.19mm(P=.011),刺激后平均直径减少率也显著降低(5.23±2.42%,P=.035)。阿夫唑嗪也导致最大瞳孔直径显著减小(0.49±0.17mm,P=.005)。坦索罗辛组收缩速度显著降低 0.70±0.20m/s(P=.001),阿夫唑嗪组收缩速度显著降低 0.54±0.18m/s(P=.004)。在扩张后测量中,只有坦索罗辛组的最大和最小瞳孔直径显著减小(分别减少 1.09±0.31mm[P=.001]和 0.89±0.36mm[P=.016])。
我们描述了一种可靠、准确和快速的方法,用于获取定量瞳孔测量值,并在白内障手术前识别使用阿夫唑嗪和坦索罗辛后发生术中虹膜松软综合征的趋势。该研究还分析了两种药物在预扩张和扩张后瞳孔动力学方面引起的相似性和差异性,表明坦索罗辛比阿夫唑嗪更能引起术中虹膜松软综合征。